Elsibucol

TargetMol
Product Code: TAR-T31615
Supplier: TargetMol
CodeSizePrice
TAR-T31615-1mg1mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-5mg5mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T31615-500mg500mg£2,633.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Elsibucol is a metabolically stable propucol derivative with antioxidant, anti-inflammatory, and anti-proliferative properties. It inhibits atherosclerosis and protects endothelial healing after arterial injury by lowering blood cholesterol levels and reducing oxidative stress and inflammation in injured arteries.
CAS:
216167-95-2
Formula:
C35H54O4S2
Molecular Weight:
602.93
Pathway:
oxidation-reduction
Purity:
0.98
SMILES:
CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCCCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C
Target:
Antioxidant

References

1. Dussault S, Dhahri W, Desjarlais M, Mathieu R, Rivard A. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation. Atherosclerosis. 2014 Nov;237(1):194-9. doi: 10.1016/j.atherosclerosis.2014.09.008. Epub 2014 Sep 16. PubMed PMID: 25244503. 2. Wang CY, Wang YT, Tzeng DW, Yang JL. Lead acetate induces EGFR activation upstream of SFK and PKCalpha linkage to the Ras/Raf-1/ERK signaling. Toxicol Appl Pharmacol. 2009 Mar 1;235(2):244-52. doi: 10.1016/j.taap.2008.12.007. Epub 2008 Dec 24. PubMed PMID: 19133285. 3. Gencer M, Ceylan E, Yildiz Zeyrek F, Aksoy N. Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease and its relation to pulmonary function tests. Respiration. 2007;74(2):170-5. Epub 2005 Dec 6. PubMed PMID: 16369121. 4. Murata S, Sundell CL, Lijkwan MA, Balsam LB, Hammainen P, Coleman C, York C, Luchoomun J, Suen KL, Howard R, Somers PK, Morris RE, Robbins RC. Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis. Transplantation. 2004 May 27;77(10):1494-500. PubMed PMID: 15239610.